News

VITESSE trial of epicutaneous (patch, in other words) immunotherapy for peanut allergy has reported successful results – this is the largest food immunotherapy trial ever performed, across US, Canada, Europe and Australia. Results have not been formally presented or published yet. This is a commercial product, called Viaskin. 654 patients between the ages of 4… Read more: Vitesse trial

Italian review of 11 studies of the use of the Anti-IgE medicine Omalizumab in oral immunotherapy (OIT) – Pharmaceuticals 2025 Mar 20;18(3):437. 3 studies looked at peanut allergy. Schneider’s study looked at 13 children aged 8-16. On the first day of OIT, all passed a 500mg dose of peanut flour! Within 8 weeks, all but… Read more: Systematic Review of Omalizumab and OIT

Helen Brough et al review the use of the Anti-IgE antibody to improve outcomes in oral immunotherapy (OIT). [J Allergy Clin Immunol Pract 2025 Apr;13(4):731-739] To begin with though, they review data on early life (pre-school) OIT. They suggest adherence is better, which I’m not convinced about, but point out that if you start early, you… Read more: Omalizumab and early life OIT

Article from Australia – remission is defined as being able to discontinue treatment for at least 8 weeks and still not have any reaction to peanut. This was a group of 162 children treated between the ages of 1 and 10 with peanut flour +/-probiotics, not Palforzia. The higher your peanut blood IgE level is… Read more: Predicting remission

Study from Canada – 69 children under the age of 3 reached maintenance dose of peanut over a median of 29 weeks (so slightly more than 6 months, on average). One patient had a peanut ingestion-related emergency department (ED) visit requiring adrenaline during initial dose escalation (first day). During the first year of maintenance phase, no… Read more: Safety of peanut OIT in young children in a clinic setting